(R)-(+)-Menthofuran is a potent, mechanism-based inactivator of human liver cytochrome P450 2A6

Drug Metabolism and Disposition

Volumn 26, Issue 7, 1998, Pages 701-704

  Khojasteh Bakht, Siamak C ^b   Koenigs, Luke L ^b   Peter, Raimund M ^b   Trager, William F ^b   Nelson, Sidney D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

COUMARIN; CYTOCHROME B5; CYTOCHROME P450; DRUG METABOLITE; IRON CHELATE; MENTHOFURAN; METALLOTHIONEIN; PULEGONE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; SCAVENGER;

ARTICLE; CONTROLLED STUDY; COVALENT BOND; DIALYSIS; ENZYME ACTIVITY; ENZYME INACTIVATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LIVER MICROSOME; LIVER TOXICITY; PRIORITY JOURNAL;

EID: 0031848620     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Anderson IB, Mullen WH, Meeker JE, Khojasteh-Bakht SC, Oishi S, Nelson SD and Blanc PD (1996) Pennyroyal toxicity: measurement of toxic metabolite levels in two cases and review of the literature. Ann Intern Med 124:726-734.
2. Bakerink JA, Gospe SM Jr, Dimand RJ and Eldridge MW (1996) Multiple organ failure after ingestion of pennyroyal oil from herbal tea in two infants. Pediatrics 98:944-947.
3. Chen W, Peter RM, McArdle S, Thummel KE, Sigle RO and Nelson SD (1996) Baculovirus expression and purification of human and rat cytochrome P450 2E1. Arch Biochem Biophys 335:123-130.
4. bdl activity. Clin Pharmacol Ther 45:34-40.
5. Gleason MN, Gosselin RE, Hodge HC and Smith RP (1969) Clinical Toxicology of Commercial Products, ed 3. Williams & Wilkins, Baltimore.
6. Gordon WP, Forte AJ, McMurtry RJ, Gal J and Nelson SD (1982) Hepatotoxicity and pulmonary toxicity of pennyroyal oil and its constituent terpenes in the mouse. Toxicol Appl Pharmacol 65:413-424.
7. Guenther E (1949) The Essential Oils. D. Van Norstrand Co., New York.
8. Jacqz-Aigrain E, Funck-Brentano C and Cresteil T (1993) CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 3:197-204.
9. Koenigs LL, Peter RM, Thompson SJ, Rettie AE and Trager WF (1997) Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. Drug Metab Dispos 25:1407-1415.
10. Miles JS, McLaren AW, Forrester LM, Glancey MJ, Lang MA and Wolf CR (1990) Identification of the human liver cytochrome P450 responsible for coumarin 7-hydroxylase activity. Biochem J 267:365-371.
11. Peter RM, Bocker R, Beaune PH, Iwasaki M, Guengerich FP and Yang CS (1990) Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P450IIE1. Chem Res Toxicol 3:566-573.
12. Rettie AE, Eddy AC, Heimark LD, Gibaldi M and Trager WF (1989) Characteristics of warfarin hydroxylation catalyzed by human liver microsomes. Drug Metab Dispos 17:265-270.
13. Sambrook J, Fritsch EF and Maniatis T (1989) Molecular Cloning: A Laboratory Manual, ed 2. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
14. Skiles GL, Oishi S and Nelson SD (1994) Epitope characterization of an anti-menthofuran antibody and use of the antibody in identification of rat hepatic protein menthofuran adducts. Toxicologist 14:112.
15. Tassaneeyakul W, Mohamed Z, Birkett DJ, McManus ME, Veronese ME, Turkey RH, Quattrochi LC, Gonzalez FJ and Miners JO (1992) Caffeine as a probe for human cytochrome P450: validation using cDNA expression, immunoinhibition and microsomal kinetic and inhibitor techniques. Pharmacogenetics 2:173-183.
16. Thomassen D, Knebel N, Slattery JT, McClanahan RH and Nelson SD (1992) Reactive intermediates in the oxidation of menthofuran by cytochrome P-450. Chem Res Toxicol 5:123-130.
17. Thomassen D, Slattery JT and Nelson SD (1988) Contribution of menthofuran to the hepatotoxicity of pulegone: assessment based on matched area under the curve and on matched time course. J Pharmacol Exp Ther 244:825-829.